GT
GBT

Glenmede Trust’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Glenmede Trust’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-761
Closed -$41K – 2447
2020
Q3 		$41K Buy
761
+164
+27% +$10.4K ﹤0.01% 1382
2020
Q2 		$37K Sell
597
-392
-40% -$26.9K ﹤0.01% 1393
2020
Q1 		$78K Hold
989
– – ﹤0.01% 1521
2019
Q4 		$78K Buy
989
+16
+2% +$948 ﹤0.01% 1521
2019
Q3 		$47 Buy
973
+400
+70% +$20.8K ﹤0.01% 1686
2019
Q2 		$30 Buy
+573
New +$32.9K ﹤0.01% 1911

Other funds holding GBT

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Glenmede Trust's GBT Position: Q4 2020 in Review

Glenmede Trust sold out of Global Blood Therapeutics, Inc. (GBT) in Q4 2020, closing a stake of 761 shares — an estimated $41K sold.

Glenmede Trust first reported a position in GBT in Q2 2019 and held it in 6 quarters. The position peaked at $78K in Q1 2020. 228 funds tracked by Wall St. Rank hold GBT as of Q4 2020.

  • Glenmede Trust reported no remaining Global Blood Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Glenmede Trust sold 761 Global Blood Therapeutics, Inc. shares in Q4 2020, an estimated $41K.
  • Glenmede Trust first reported a position in Global Blood Therapeutics, Inc. in Q2 2019 and held it in 6 quarters.
  • Glenmede Trust's Global Blood Therapeutics, Inc. position peaked at $78K in Q1 2020.
  • 228 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q4 2020.

Based on Glenmede Trust's 13F filing for Q4 2020, filed 16 Feb 2021.